A Phase 3 interventional study of Berobenatide and Placebo in Apnea, Sleep Disorders and Overweight and/or Obesity, sponsored by Pfizer. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 754 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 161 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.
Among the 754 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 69th largest by planned enrollment of the 595 interventional ones that give a count, is one of 42 that started in 2026, is one of 39 in phase 3, reaches primary completion later than 131 of the 160 other live ones, and was the 750th registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →127 of the 754 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:
Nevada Dental Sleep · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–40 · Women only
Fisher and Paykel Healthcare · Sites in United States
Ages 22+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Sairam Parthasarathy · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
754 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 85 · Phase 3 45 · Phase 4 36
First in 1999; this study’s year is marked. 42 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 49 across the 595 interventional studies, 81 across the 157 observational. Of the 512 that completed or were terminated, 257 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
192 of 754 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
66 of the studies in Sleep Apnea, Obstructive with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07613281Serene Sleep, Inc.Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA). | 2026-11 |
| NCT04814420Tulane UniversityAtrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study | 2026-11 |
| NCT07103941Isabel Moreno HayIOA Preventing Occlusal Changes With MAD Use | 2026-11-28 |
Add all 66 to your calendar (.ics) → With an account.
Among the 754 studies in Sleep Apnea, Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea [OSA]) and overweight or obesity who are not using a breathing machine (positive airway pressure [PAP] machine).
People may be able to take part if they are adults with moderate to severe OSA, have overweight or obesity, and have been unable or unwilling using PAP therapy before joining the study. Participants will be assigned by chance to receive either berobenatide or a placebo (a treatment that looks like the study medicine but contains no active medicine). The study treatment will be given as an injection under the skin approximately once a month. Participants will receive study treatment at study sites and may administer some doses at home after receiving training.
During the study, participants will attend study visits, undergo sleep studies, complete questionnaires, and have health assessments performed. Researchers will compare the effects of berobenatide and placebo on sleep apnea, body weight, and other health measures.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
This study's planned enrollment of 258 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Sleep Apnea, Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Apnea. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive berobenatide by subcutaneous injection.
Drug: Berobenatide
Participants receive volume-matched placebo
Drug: Placebo
Subcutaneous injection
Also known as: PF-08653944, MET097
Volume-matched subcutaneous placebo.
Change From Baseline in Apnea-Hypopnea Index
Apnea-Hypopnea Index is the number of apnea and hypopnea events per hour of sleep, assessed by polysomnography.
Time frame: Baseline, Week 52
Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 52
Change From Baseline in High-Sensitivity C-Reactive Protein
Time frame: Baseline, Week 52
Percent Change From Baseline in Apnea-Hypopnea Index
Time frame: Baseline, Week 52
Percentage of Participants With at Least 50% Reduction in Apnea-Hypopnea Index
Time frame: Week 52
Change From Baseline in Sleep-Apnea-Specific Hypoxic Burden (SASHB)
Time frame: Baseline, Week 52
Percentage of Participants With Obstructive Sleep Apnea Remission or Mild Non-Symptomatic Obstructive Sleep Apnea
Time frame: Week 52
Change From Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a T-Score
Time frame: Baseline, Week 52
Change From Baseline in PROMIS Sleep Disturbance 8b T-Score
Time frame: Baseline, Week 52
Percentage of Participants with AHI <5
Time frame: Week 52
Percentage of Participants with AHI 5-14 with ESS (Epworth Sleepiness Scale) ≤10
Time frame: Week 52
Percentage of participants with AHI less then 15
Time frame: Week 52
Change From Baseline in Epworth Sleepiness Scale Total Score
Time frame: Baseline, Week 52
Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) Physical Function Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Physical Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Psychosocial Composite Score
Time frame: Baseline, Week 52
Change From Baseline in IWQOL-Lite-CT Total Score
Score ranges from 0 to 100; higher scores indicate better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Body Weight
Time frame: Baseline, Week 52
Change From Baseline in Body Mass Index
Time frame: Baseline, Week 52
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 52
Change From Baseline in Neck Circumference
Time frame: Baseline, Week 52
Change From Baseline in Short Form 36-Item (SF-36)
Time frame: Baseline, Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Sleepiness Category
Time frame: Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Fatigue Category
Time frame: Week 52
Percentage of Participants With Improvement in Patient Global Impression of Severity (PGI-S) Snoring Category
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleepiness
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Fatigue
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Sleep Quality
Time frame: Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) Snoring
Time frame: Week 52
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Time frame: Baseline, Week 52
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Presenteeism Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Work Productivity Loss Score
Time frame: Baseline, Week 52
Change From Baseline in WPAI:GH Activity Impairment Score
Time frame: Baseline, Week 52
Number of participants with Treatment-Emergent Adverse Event (TEAE)
Time frame: Week 52
Number of participants with Serious Adverse Event (SAE)
Time frame: Week 52
Number of participants with Adverse event (AE) leading to permanent discontinuation from study intervention or study
Time frame: Week 52
Number of participants with Adverse Events of Special Interest (AESI)
Time frame: Week 52
Number of participants with clinical laboratory abnormalities
Time frame: Week 52
Change From Baseline in Diastolic Blood Pressure
Time frame: Baseline, Week 52
Change From Baseline in Total Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Time frame: Baseline, Week 52
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Time frame: Baseline, week 52
Change From Baseline in Non-HDL Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Time frame: Baseline, Week 52
Change From Baseline in Triglycerides
Time frame: Baseline, Week 52
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 19 months after the start.
Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's planned 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide